DeepMed Research

MEDI-3617

Generic Name: MEDI-3617

Clinical Trials

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Phase 1

Completed

Conditions: Metastatic Melanoma

Interventions: Drug: Tremelimumab
Drug: MEDI3617

First Posted Date: 2014-05-19

Last Posted Date: 2023-05-01

Lead Sponsor: F. Stephen Hodi, MD

Target Recruit Count: 15

Registration Number: NCT02141542

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors
Advanced Recurrent Ovarian Tumors

Interventions: Drug: MEDI3617
Drug: Paclitaxel
Drug: Bevacizumab
Drug: Carboplatin

First Posted Date: 2010-11-25

Last Posted Date: 2017-03-29

Lead Sponsor: MedImmune LLC

Target Recruit Count: 162

Registration Number: NCT01248949

Locations: 🇺🇸
Research Site, Nashville, Tennessee, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy